John Martin Magenau, MD

Dr. Magenau is currently an Assistant Professor at the University of Michigan and the Adult Clinical BMT director of the Blood and Marrow Transplantation Program. He holds a Bachelor of Science in Biology from Pennsylvania State University, and obtained his M.D. from the Temple University in Philadelphia, Pennsylvania. Dr. Magenau then trained in internal medicine at the University of Illinois in Chicago.

Dr. Magenau is the lead clinical investigator on several trials including experience in clinical HCT, responsible research practices, team science, and conducting multicenter prospective HCT clinical trials in high risk populations (Acute Myeloid Leukemia not in remission at time of HCT). He also has a background in developing, performing, and monitoring HCT studies that integrate immune analysis of human samples. 

Hematology (Internal Medicine), Medical Oncology, Internal Medicine

University of Michigan Health participates with most health insurance plans.

Dr. Magenau’s interest is patient-centered investigations designed to improve the immunotherapeutic potential of allogeneic hematopoietic cell transplantation (HCT). Specifically, his group directly translates emerging preclinical knowledge of HCT immune biology into proof-of-concept human clinical trials. These studies focus on clinical approaches designed to mitigate allogeneic graft-versus-host disease (GVHD) responses while retaining (or enhancing) functional immunity against infection and malignancy.